Shigatoxin 1 anticorps

N° du produit ABIN2192153

Détail du produit

Antigène: Shigatoxin 1

Reactivité: Shigella dysenteriae

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Inconjugué

Application: Western Blotting (WB), Immunoassay (IA), Inhibition Assay (InhA)

Stérilité: 0.2 μm filtered

Clone: 13C4

Information d'application

Indications d'application: For Western blotting dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:10. For inhibition of biological activity in vitro dilutions have to be made according to the amounts of toxin to be inactivated.

Restrictions: For Research Use only

Stockage

Buffer: PBS, containing 0.1 % bovine serum albumin.

Stock: 4 °C

Stockage commentaire: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.

Date de péremption: 12 months

Référence

Smith, Teel, Carvalho, Melton-Celsa, OBrien: "Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2." dans: Vaccine, Vol. 24, Issue 19, pp. 4122-9, (2006) (PubMed).

Strockbine, Marques, Holmes, OBrien: "Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli." dans: Infection and immunity, Vol. 50, Issue 3, pp. 695-700, (1986) (PubMed).

Détail du antigène

Antigène: Shigatoxin 1

Sujet: The monoclonal antibody 13C4 recognizes the 1B subunit of Shiga-like toxin 1. Shiga-like toxins (SLTs), are also called Verotoxins. Enterohemorrhagic Escherichia coli (EHEC) strains which are primarily of serotypes 0157:H7, 026:H11 and O111:H8 have been incriminated as etiologic agents of hemorrhagic colitis and Hemolytic-uremic syndrome, a generalized disease characterized by acute renal failure, thrombocytopenia, and microangiopathic hemolytic anemia. There are several distinct E.coli SLTs. SLT-I and SLT-II are produced by EHEC. SLT-I and Shiga toxin share >99 % deduced amino acid sequence homology, whereas SLT-I and SLT-II share about 60 % deduced amino acid sequence homology. SLT-I and SLT-II are antigenically distinct. The protein structure of the toxin consists of two domains: the A polypeptide that inhibits protein synthesis by targeting ribosomes, and the B polypeptide pentamer that binds to the eukaryotic cell receptor globotriaosylceramide (Gb3) leading to receptor-mediated endocytosis.